BIOC - バイセプト (Biocept Inc.) バイセプト

 BIOCのチャート


 BIOCの企業情報

symbol BIOC
会社名 Biocept Inc (バイセプト)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 Biocept Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA) assays utilizing a standard blood sample or liquid biopsy. The Company''s Target-Selector offering is based on an internally developed microfluidics-based CTC capture and analysis platform with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications such as breast cancer non-small cell lung cancer (NSCLC) small cell lung cancer (SCLC) gastric cancer colorectal cancer prostate cancer and melanoma.   バイセプトは米国の商品化段階のがん診断会社。標準的な血液サンプルを用いた、独自の循環腫瘍細胞(CTC)及び循環腫瘍DNA(ctDNA)検査を開発・商品化。組織採取が困難な患者から、血液だけでの病理診断が可能となる。異なるタイプのがんと臨床現場においての、がん診断検査の新プラットフォ―ムの開発と技術強化に焦点を当てる。   Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, including metastatic tumors involving lung, breast and the central nervous system. Biocept's patented Target Selector™ technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity and specificity than most commercial assays. Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 PCR testing to support public health efforts during this unprecedented pandemic.
本社所在地 5810 Nancy Ridge Drive San Diego CA 92121 USA
代表者氏名 Michael W. Nall マイケル・W・ナル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-320-8200
設立年月日 35551
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数
url www.biocept.com
nasdaq_url https://www.nasdaq.com/symbol/bioc
adr_tso
EBITDA EBITDA(百万ドル) -22.91521
終値(lastsale) 2.36
時価総額(marketcap) 5385911.76
時価総額 時価総額(百万ドル) 7.30705
売上高 売上高(百万ドル) 3.73582
企業価値(EV) 企業価値(EV)(百万ドル) 6.79433
当期純利益 当期純利益(百万ドル) -21.37632
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Biocept Inc revenues decreased 45% to $1.6M. Net loss increased 24% to $12.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase of 31% to $2.1M (expense) Other income decrease from $38K (income) to $30K (expense).

 BIOCのテクニカル分析


 BIOCのニュース

   Plus Therapeutics inks contract to use Biocept''s test for use in cancer trial  2022/06/22 13:00:53 Seeking Alpha
Plus Therapeutics (PSTV) signed a multi-year agreement to use Biocept''s (BIOC) cerebrospinal fluid ((CSF)) assay CNSide in its phase 1/2a trial called ReSPECT-LM of…
   Biocept GAAP EPS of -$0.16 beats by $0.08, revenue of $19.95M beats by $8.46M (NASDAQ:BIOC)  2022/05/23 20:39:54 Seeking Alpha
Biocept press release (BIOC): Q1 GAAP EPS of -$0.16 beats by $0.08.Revenue of $19.95M (+12.3% Y/Y) beats by $8.46M.Biocept reported cash and cash equivalents as of March 31, 2022…
   Biocept Reports First Quarter 2022 Financial Results  2022/05/23 20:05:00 Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months
   Biocept reports delay in filing of Q1 report on Form 10-Q (NASDAQ:BIOC)  2022/05/16 20:27:44 Seeking Alpha
Biocept (BIOC) has reported a delay in the filing of its Q122 quarterly report on Form 10-Q.The delay is related to the ongoing accounting review of Biocept’s financial statements as of…
   Liquid Biopsy Market 2022 Top Leading Players, Recent Developments, Opportunities, Size, Revenue, Sales, Regional Analysis, Business Strategies, Challenges, Types, Applications  2022/04/07 06:17:27 Benzinga
Pune, April 07, 2022 (GLOBE NEWSWIRE) -- Global Liquid Biopsy Market report is expert study that can deliver you with an elaborate analysis of the Liquid Biopsy. The report covers information about top players, projected size of the market, data and figures to update about where opportunities are in the market, competitor analysis and vendor information. Also, it offers a complete analysis of the key market dynamics, with growth drivers, challenges, restraints, opportunities and trends. Furthermore, receive exact details and statistics associated to Liquid Biopsy market and its key factors such as revenue, growth, compound annual growth, year-over-year developments, consumption, and production. The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years.
   Liquid Biopsy Market revenue to cross USD 10 Bn by 2027: Global Market Insights Inc.  2021/12/01 09:30:00 Intrado Digital Media
Major liquid biopsy market players include BIOCEPT, Inc., QIAGEN, Myriad Genetics, Inc., Lucence health Inc., Guardant Health, Inc. and F. Hoffmann-La Roche. Major liquid biopsy market players include BIOCEPT, Inc., QIAGEN, Myriad Genetics, Inc., Lucence health Inc., Guardant Health, Inc. and F. Hoffmann-La Roche.
   Biocept (NASDAQ:BIOC) Lifted to C- at TheStreet  2021/11/26 06:10:41 Transcript Daily
TheStreet upgraded shares of Biocept (NASDAQ:BIOC) from a d rating to a c- rating in a research report sent to investors on Tuesday morning, TheStreetRatingsTable reports. Several other analysts have also issued reports on BIOC. Brookline Capital Acquisition restated a buy rating on shares of Biocept in a research note on Saturday, October 9th. Brookline []
   Global Gastric Cancer Diagnostics Market Estimated $1,597.69 Million Growth By 2028||Players-Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC & Others  2021/11/25 07:57:41 OpenPR
The Gastric Cancer Diagnostics report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2028. The
   Biocept, Inc. (NASDAQ:BIOC) Short Interest Down 17.9% in October  2021/11/23 06:46:41 Dakota Financial News
Biocept, Inc. (NASDAQ:BIOC) was the recipient of a significant decrease in short interest during the month of October. As of October 29th, there was short interest totalling 461,900 shares, a decrease of 17.9% from the October 14th total of 562,900 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently []
   Biocept launches combined COVID-19 and influenza test  2021/11/22 14:27:49 Seeking Alpha
   Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/09/01 00:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees. These inducement stock options have a grant date of August 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement sto
   Proactive news headlines including BioHarvest Sciences, Biocept, Nomad Royalty, The Valens Company, Plurilock Security and Western Magnesium  2021/08/19 18:23:00 Intrado Digital Media
New York , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:
   Investors React Positively To Study Data Of Biocept''s Cerebrospinal Fluid Assay  2021/08/19 15:37:29 Benzinga
Biocept Inc (NASDAQ: BIOC ) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis. The study will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology. Related: Full story available on Benzinga.com
   Biocepts CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer  2021/08/19 12:34:00 Wallstreet:Online
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the companys cerebrospinal fluid assay, CNSide, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes and extend life expectancy. The study will
   Biocept Stock Drops Despite Clocking Q2 Sales Of $12M  2021/08/17 15:22:22 Benzinga
Biocept Inc (NASDAQ: BIOC ) reported its second-quarter revenues of $12 million , compared to a mere $917,471 a year ago, but sharply missing the consensus of $17.76 million. The revenue growth is attributable to RT-PCR COVID-19 testing, as only $926,000 in revenue came from oncology testing. Related: Medicare Issues Coverage Determination For Biocept''s Target Selector Assay For Breast Cancer . The Full story available on Benzinga.com

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 バイセプト BIOC Biocept Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)